All Videos

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Nayan Patel, PharmD, reveals how innovative glutathione delivery transforms skin care, combats oxidative stress, and empowers skin health for lasting results.

Discover how Auro GSH by Nayan Patel, PharmD, revolutionizes glutathione delivery in skin care, targeting oxidative stress for healthier skin.

A panelist presents a case of severe, chronic facial seborrheic dermatitis in a young man, highlighting diagnostic challenges and emotional impact, and illustrating how daily use of a phosphodiesterase-4 (PDE4) inhibitor foam led to near-clearance and symptom relief by 8 weeks, underscoring the therapy’s effectiveness, safety, and adaptability to patient preferences.

Panelists discuss the structure and function of the skin barrier, highlighting key components like filaggrin and aquaporins, and emphasizing the need to protect against both environmental and lifestyle-related stressors—collectively known as the exposome—to maintain hydration and support long-term skin health.

Panelists discuss the critical role of maintaining a healthy skin barrier in managing sensitive skin, emphasizing the importance of gentle, evidence-based cleansing and moisturizing practices to prevent irritation, support barrier repair, and improve dermatologic outcomes.

Discover the benefits of RetaXome therapy for sensitive skin and its potential in skin care routines.

Novel formulations like retinal-infused exosomes represent an evolution rather than a replacement of retinoid therapy.

A panelist presents a case of severe seborrheic dermatitis in a young man with facial and scalp involvement, demonstrating how a once-daily, foam-based phosphodiesterase-4 (PDE4) inhibitor provided rapid, complete clearance and itch relief, highlighting the importance of efficacy, cosmetic acceptability, and quality-of-life considerations in treatment selection.

Sofia Wenzler, PhD, highlights the vital role dermatologists play in treating body-focused repetitive behaviors like skin picking and hair pulling.

Vimal Prajapati, MD, FRCPC, DABD, highlighted key findings from the THRIVE-AA trials, noting the efficacy of deuruxolitinib 8 mg BID, its favorable safety profile, and its positioning alongside other JAK inhibitors.

Panelists discuss how evolving concerns about long-term topical corticosteroid use are prompting a shift toward safer, nonsteroidal alternatives such as roflumilast, emphasizing structured treatment plans, early patient education, and improved office workflows to support individualized, steroid-sparing psoriasis care that enhances both outcomes and trust.

Vimal Prajapati, MD, FRCPC, DABD, reviews the mechanism of action, clinical trial outcomes, monitoring considerations, and safety profile of recently available deuruxolitinib.

Sofia Wenzler, PhD, addresses misconceptions about dermatillomania (skin picking) and trichotillomania (hair pulling), advocating for compassionate care and accessible treatment for BFRBs.

A panelist highlights the evolution of seborrheic dermatitis treatment from traditional antifungals and corticosteroids to newer nonsteroidal options such as phosphodiesterase-4 (PDE4) inhibitors, emphasizing the importance of aligning therapy with patient preferences, lifestyle factors, and long-term disease management needs to improve adherence and outcomes.

Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, of the National Eczema Association discuss how the EczemaWise app integrates patient-reported outcomes, validated tools, and real-world data to improve collaboration between patients and clinicians in managing eczema.

Discover the latest in regenerative aesthetics and body contouring at DERM 2025, featuring insights from Suneel Chilukuri, MD, on skin care trends and biohacking.

Panelists discuss how the availability of both roflumilast foam and cream allows for personalized, preference-driven treatment plans that enhance adherence while streamlined access strategies and improved topical efficacy are reshaping the role of nonsteroidal agents in psoriasis care, extending their use beyond mild disease to special sites and even as systemic-sparing options.

GLP-1 receptor agonists may indirectly affect dermatologic outcomes by targeting inflammation and metabolic comorbidities.

Members of Elevate-Derm Alliance and the SkinSync podcast discuss the inspiration behind the podcast and how it best serves dermatology clinicians.

Lisa Swanson, MD, FAAD, shares innovative insights on pediatric dermatology, emphasizing effective treatments and communication strategies for young patients at DERM 2025.

An expert discusses how insurance limitations hinder access to newer, more effective acne treatments, emphasizing the need for long-term cost-benefit recognition, while also highlighting the ongoing role of oral antibiotics and the importance of personalized care—especially for adult women with distinct acne profiles.

An expert discusses recent innovations in acne treatment—including the first narrow-spectrum oral antibiotic, an advanced triple-combination topical, and emerging procedural options—highlighting their roles in personalized care, antibiotic stewardship, and achieving long-term therapeutic success.

Case reports showed encouraging outcomes in eczema, but the company is pursuing deeper validation.

Discover how biologic coordinators streamline dermatologic care through detailed protocols, clinical documentation, and patient advocacy to improve access to life-changing biologic therapies.

A panelist discusses the diverse clinical presentation and complex pathophysiology of seborrheic dermatitis, emphasizing the need for individualized, location-specific treatment strategies and highlighting how emerging therapies may help address overlapping features with other chronic inflammatory skin conditions.

April Martinez-Dulay, MSN, APRN, FNP-BC, shares insights on diagnosing and treating types of dermatitis at DERM 2025, emphasizing innovative approaches and patient care strategies.

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.

Strong mentorship provides resilience for young clinicians navigating evolving challenges in practice.

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.